Short answer
TuHURA Biosciences, Inc./NV (HURA) filed an 8-K current report with the SEC on November 13, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q3 2026 financial results for the three months ended September 30, 2026.
TuHURA Biosciences, Inc./NV 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q3 2026 financial results for the three months ended September 30, 2026
- Corporate update accompanying the quarterly results
- Detailed figures and operational developments in Exhibit 99.1
Item EX-99.1 · Exhibit EX-99.1
- Q3 2026 results: cash $1.9M, with $9.2M drawn on Parkview’s credit facility
- Parkview facility provided $5.6M during Q3, supporting operations without immediate equity dilution
- IFx-2.0 showed partial responses in all first 3 metastatic Merkel cell carcinoma patients, ongoing beyond six months
- FDA cleared Phase 1b TBS-2025 study in relapsed/refractory mutated NPM1 AML, enabling clinical validation of the VISTA program
- Operating cash outflow $18.1M for nine months, while shares outstanding reached approximately 65.8M
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other TuHURA Biosciences, Inc./NV 8-K filings
Get the next HURA 8-K as it lands
Follow HURA for push alerts, or ask the research agent what this filing means.